Recent Research Development of Imeglimin as Oral Hypoglycemic Agent (OHA)

Abstract

As a novel oral hypoglycemic agent (OHA), imeglimin (Twymeeg) has recently been introduced into clinical practice. It has shown improved glucose variability via a mitochondrial mechanism. Adequate daily doses identified in several investigations are 1000 mg or 1500 mg twice a day (BID). Consequently, 1000 mg BID seems to be recommended in light of tolerability, safety, and gastrointestinal adverse effects (GI-AEs). For hemodialysis (HD) patients, 500 mg/day was tried with clinical effect. To minimize GI-AEs, novel research has explored the adaptation of nanofiber disintegration for the drug delivery system (DDS). This method takes only 2 +/- 1 seconds via buccal route administration.